Metabolic Muscle Diseases

Nov. 18th, 2011 12:25 am
healthy_back: (Default)
[personal profile] healthy_back
http://william322.livejournal.com/13173.html

Знакомтесь, - Metabolic Muscle Diseases. Походу мой случай. Либо метаболик, либо аутоиммюн. У меня всегда с детства была слабая выносливость, и в 10 лет, когда в футбол играл и в 19 в каратэ. Очень слабая, сколько ни тренировался, не улудшалась. Походу у меня, что-то типа denosine monophosphate deaminase deficiency type 1.


Они могут протекать бессимптомно. Походу всегда была такая штука, может генетическая, а веганская диета была триггером. Теперь надо понять, что у меня конкретно. Мало времени осталось, надеюсь, успею.

Похоже когда у меня давление было, пострадала  pituitary gland и был

Hypopituitarism в частности гипотириоз, надо будет потом ещё почитать.

Пришлос 20 баксов отдать за доступ к статьям. Хороший сайт, но платный.

Approach to the metabolic myopathies

Disclosures

Last literature review version 19.2: May 2011 | This topic last updated: February 17, 2011 (More)

INTRODUCTION — Most patients with a metabolic myopathy (eg, glycogen storage diseases, carnitine palmitoyltransferase deficiency) have dynamic rather than static symptoms, and therefore usually complain of exercise intolerance, muscle pain and cramps rather than fixed weakness with exercise. Nevertheless, some patients may develop progressive muscular weakness that is usually proximal, mimicking inflammatory myopathy or limb girdle muscular dystrophy, but is sometimes distal. In a smaller group of patients, both dynamic and static symptoms predominate (table 1).

This topic review will provide an overview of the evaluation of the patient with a suspected metabolic myopathy. A general approach to the diagnosis of metabolic myopathies is presented in Figure 1 (figure 1). Detailed descriptions of the different disorders are presented separately. (See "Overview of disorders of glycogen metabolism" and "Causes of metabolic myopathies".)

An overview of the biochemistry of energy metabolism in muscle is also discussed elsewhere. (See "Energy metabolism in muscle".)

OVERVIEW OF CLINICAL MANIFESTATIONS — The symptoms, signs, and laboratory abnormalities resulting from a metabolic myopathy vary with the underlying defect. The diagnosis of these disorders depends upon a constellation of findings, including the type of muscle involvement, specific laboratory abnormalities (particularly elevations in serum creatine kinase and myoglobinuria), patient age, family history, and the results of histologic and pathologic examinations.

Glycolytic/glycogenolytic disorders — In patients with defects of carbohydrate metabolism, muscle symptoms are induced by either brief isometric exercise, such as lifting heavy weights, or by less intense but sustained dynamic exercise, such as swimming, climbing stairs, or running. Acute muscle breakdown may lead to myoglobinuria, cramps, and muscle swelling.

In young children, defects in glycogenolysis may present with liver dysfunction, hepatomegaly, failure to thrive, hypoglycemia (sometimes with associated hypoglycemic seizures), gross motor delay, peripheral neuropathy, cardiac involvement, hemolytic anemia with jaundice, splenomegaly, and myoglobinuria. Mental retardation, upper and lower motor neuron involvement with sensory loss, sphincter problems, and neurogenic bladder may also be observed.

The principal symptoms and signs, however, are those related to exercise intolerance and recurrent myoglobinuria [1,2]. Patients with defects of glycogen metabolism usually complain of easy fatigability upon exertion and, occasionally, of muscle stiffness induced by exercise. In some cases, brief rest when muscle symptoms develop can subsequently result in improved exercise tolerance, referred to as the spontaneous "second wind" [3]. "Second wind" also can be induced by the infusion of carbohydrate fuel (eg, glucose) or lipids [4].

Patients with certain glycolytic defects (eg, muscle phosphofructokinase deficiency), however, are unable to achieve a spontaneous second wind [5] or have worsening of symptoms after the administration of glucose (the "out of wind" phenomenon") [6]. (See "Overview of disorders of glycogen metabolism" and "Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)".)

Disorders of lipid metabolism — The metabolic myopathies resulting from disorders of lipid metabolism include:

  • Defects of beta-oxidation enzymes
  • Carnitine deficiency syndromes
  • Fatty acid transport defects

(See "Causes of metabolic myopathies".)

With disorders of lipid metabolism, symptoms are usually induced by prolonged exercise and prolonged fasting. These patients, in contrast to those with glycogen metabolism defects, do not develop true muscle cramps or contractures, and do not experience a "second wind." Their symptoms and signs, such as muscle pain, tightness, or myoglobinuria, are usually induced by infection, general anesthesia, exposure to cold, and a low-carbohydrate, high-fat diet [7].

Some investigators have suggested that there are four main clinical and laboratory features that should lead the clinician to suspect a fatty acid oxidation disorder [8]:

  • Involvement of fatty acid oxidation-dependent tissues, such as the heart, muscle, and liver
  • Recurrent episodes of hypoketotic hypoglycemia (ketoacidosis does not occur because fatty acids cannot be converted to ketoacids in the liver)
  • Acute metabolic decompensation in association with fasting
  • Alterations in plasma and tissue concentrations of carnitine

Skeletal muscle, heart, and liver are highly dependent upon efficient fatty acid utilization. Fatty acids are a major source of energy for the heart and liver, particularly during fasting when glycogen and glucose stores have been depleted. In addition, resting muscle and exercising muscle during mild to moderate prolonged exercise derive most of the required energy from fatty acid oxidation. (See "Energy metabolism in muscle".)

Among fasting patients with fatty acid oxidation defects, the free fatty acids cannot be metabolized because of the existing metabolic block; as a result, they are stored in the cytoplasm as triglycerides, thereby resulting in progressive lipid storage myopathy with weakness, hypertrophic and/or dilated cardiomyopathy, and fatty liver. In addition, with fasting, glucose and glycogen stores are depleted and ketone bodies are not generated because of the existing metabolic block. As a result, the ratio of serum free fatty acids to ketones increases from the normal ratio of 1:1 to more than 2:1, which is highly suggestive of a block in beta-oxidation [1,9].

Other conditions that can lead to metabolic decompensation among patients with fatty acid oxidation defects include cold-induced shivering thermogenesis and infection with vomiting:

  • With cold exposure, shivering depends heavily upon long-chain fatty acid oxidation [7]
  • After prolonged fasting or during infections, children can become comatose and present with Reye-like syndrome symptoms

Serum carnitine levels vary with the various defects of lipid metabolism. With carnitine transport defects, for example, total serum carnitine is significantly reduced (eg, less than 5 percent of normal) and the esterified fraction is normal [10]. This finding is probably related to both reduced renal carnitine reabsorption (leading to carnitine leak), and defective intestinal carnitine absorption.

By comparison, in the majority of cases of intramitochondrial beta-oxidation defects, the amount of total serum carnitine is reduced to less than 50 percent of normal, and the esterified carnitine fraction is increased to more than 50 percent of normal (normal: 10 to 25 percent in the fed state and 30 to 50 percent during fasting) [8]. This occurs because the accumulating longer-chain-length acylcarnitines are reabsorbed much more easily at the renal tubular reabsorptive site than free carnitine. As a result, the free carnitine fraction will be reduced (table 2) [11].

Myoglobinuria and rhabdomyolysis — Acute muscle breakdown of sufficient severity can lead to myoglobinemia and myoglobinuria [12]. The urine acquires a brownish, cola-like color, and the supernatant is positive for heme in the absence of red blood cells in the sediment. This heme-pigment- based assay has a sensitivity of 81 percent for detection of rhabdomyolysis [13]. The diagnostic approach to myoglobinuria and rhabdomyolysis is discussed in detail separately. (See "Red to brown urine: Hematuria; hemoglobinuria; myoglobinuria" and "Clinical manifestations, diagnosis, and causes of rhabdomyolysis".)

Rhabdomyolysis may also occur in the absence of overt myoglobinuria, even when myoglobin is undetectable in the urine by qualitative or semiquantitative assay [14]. The sensitivity of the ultrafiltration/dipstick urine myoglobin assay is relatively low (22 percent) [13]. However, myoglobin can be detected quantitatively in the serum. The rise in serum myoglobin precedes the rise in creatine kinase (CK); the clearance of myoglobin from plasma via renal excretion and metabolism to bilirubin is rapid and may be complete within one to six hours. Therefore, urine and serum myoglobin may not be detectable by the time of evaluation [14].

Serum CK is usually highly elevated (more than 5 to 100 times normal), with associated hyperuricemia, hyperphosphatemia, and hypocalcemia. The patient may or may not have any muscle symptoms or signs such as stiffness, cramps, aches, or swelling.

Patients with myoglobinuria may develop acute renal failure. Renal failure may be preventable with aggressive hydration and alkalinization of the urine. Hypercalcemia can occur during recovery of renal function in patients who develop renal failure. (See "Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)", section on 'Prevention' and "Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)", section on 'Calcium'.)

In addition to the risk of acute renal failure, some patients develop respiratory failure, cardiac arrhythmias, or sometimes coma.

The frequency of myoglobinuria due to a metabolic defect may vary among children and adults. In a large series of children with recurrent myoglobinuria, an enzyme abnormality could be detected in only 24 percent of the cases [15]; by comparison, a similar adult series of 77 patients found a biochemical abnormality in 47 percent [16]. The most common metabolic cause of recurrent myoglobinuria in both adults and children is carnitine palmitoyltransferase II deficiency.

In addition to genetically determined muscle metabolic defects, common causes of rhabdomyolysis are toxins, alcohol, drugs, muscle compression, overexertion, or inflammatory processes. Both viral (influenza A and B, Epstein-Barr, HIV, adenovirus, cytomegalovirus, echovirus, coxsackievirus, parainfluenza, herpes simplex) and autoimmune (dermatomyositis, polymyositis) inflammatory etiologies have been implicated. Hypothyroidism may lead to rhabdomyolysis and myoglobinuria, and a few cases related to thyrotoxicosis have also been described [17]. (See "Clinical manifestations, diagnosis, and causes of rhabdomyolysis".)

Toxins appear to be the most frequent cause of rhabdomyolysis. In a series of 475 hospitalized adults with rhabdomyolysis, the following observations were made [14]:

  • The most frequent etiology was an exogenous toxin (46 percent), a category that included alcohol, illicit drugs, and prescribed drugs (eg, antipsychotics, statins, zidovudine, colchicine, selective serotonin reuptake inhibitors and lithium) [14]. Less common causes included trauma, seizures, immobility, critical illness myopathy, exercise, heat/dehydration, and hypothermia. Multiple factors could be identified in 60 percent of cases.
  • An underlying myopathy or metabolic muscle defect was diagnosed in only 10 percent of the patients [14]. In this group, recurrences were common, the incidence of acute renal failure was low, and typically only one etiologic factor could be identified. Myoglobinuria was detected by dipstick/ultrafiltration in 19 percent of the patients.

In a series of 191 children treated in the emergency department of a pediatric tertiary care hospital, the most common causes of rhabdomyolysis were viral myositis, trauma, and connective tissue diseases, found in 38, 26, and 5 percent, respectively [18]. Among children with CK values ≥6000 IU/L, a genetically determined metabolic myopathy or undiagnosed dermatomyositis was present in 6 of 37 (16 percent), while in children with CK levels of 1000 to 5999 IU/L, the proportion was 10 of 154 (6 percent). The incidence of acute renal failure in children in this study (4.7 percent) [18] was much lower than that reported in the adult series (46 percent) [14] discussed above.

Myoglobinuria may also occur in patients with dystrophinopathies or caveolinopathies (ie, limb-girdle muscular dystrophy type 1C) [19]. (See "Limb-girdle muscular dystrophy".)

Although exercise intolerance, often dating back to childhood, is common in patients with mitochondrial defects, rhabdomyolysis with resultant myoglobinuria is rare [20]. However, myoglobinuria has been reported in patients with mutations involving cytochrome b, cytochrome c oxidase (cox), and the MELAS A3260G mutation [21-23]. Exercise intolerance itself is often overshadowed by more debilitating manifestations of mitochondrial diseases, but can be exacerbated under conditions of intercurrent infection or fasting. In certain patients, weakness can be persistent. (See "Mitochondrial myopathies: Clinical features and diagnosis".)

SYMPTOM ASSESSMENT — When confronted with a patient with a possible metabolic myopathy, the first step is to determine whether the symptoms are dynamic, static, or both (table 1) [24]:

  • Patients with dynamic symptoms develop acute and recurrent episodes of irreversible muscle dysfunction related to exercise intolerance, prolonged fasting, exposure to cold, general anesthesia, intercurrent infection, or low-carbohydrate, high-fat diet. Some of these patients may develop myoglobinuria. In between episodes, the patients are free of symptoms.
  • Static symptoms include proximal weakness (which is indistinguishable from limb-girdle muscular dystrophies), occasionally distal weakness, generalized muscle weakness, and respiratory difficulties related to involvement of respiratory muscles or fixed cardiomyopathy (as in acid maltase deficiency). Other static features include progressive external ophthalmoplegia, peripheral neuropathies, seizures, developmental delay, failure to thrive, short stature, deafness, and ataxia. The symptoms themselves are not necessarily static since progression of varying degree usually occurs depending upon the severity and type of defect.

Both dynamic and static symptoms are common in mitochondrial myopathies related to either mitochondrial DNA defects or specific inborn errors of fatty acid oxidation [1].

The second step is targeted at determining the type of the underlying biochemical abnormality as suggested by the pattern of symptoms (figure 1). As examples:

  • Patients who develop symptoms after prolonged, mild to moderate, low-intensity activity (such as walking) may have a defect in fatty acid oxidation (especially if the symptoms occur after one hour).
  • Symptoms developing during or after high-intensity isometric exercise (such as pushing a stalled car or lifting weights) or high-intensity, sustained, submaximal exercise (such as sprinting) suggest a defect in glycogen and/or glucose metabolism; these symptoms tend to occur early in the course of the activity.
  • Defects in glucose, glycogen, or fatty acid metabolism may be observed among patients with symptoms produced by low-intensity, submaximal exercise (eg, running slowly).

The Table provides a list of the various biochemical defects, categorized on the basis of the symptoms they produce (table 1). The general approach to the patient with and the differential diagnosis of muscle weakness is presented separately. (See "Approach to the patient with muscle weakness".)

LABORATORY TESTING — The laboratory investigation of patients with suspected metabolic myopathies includes serum and urine testing, the forearm ischemic exercise test, electromyography, muscle biopsy, and, in some cases, nuclear magnetic resonance spectroscopy, if available (table 3).

Other etiologies (eg, toxic, traumatic, alcohol- and drug-related, endocrine, viral and inflammatory) should be considered and appropriate testing should be performed to exclude them prior to investigating a metabolic etiology.

Serum and urine testing — Abnormal levels of specific compounds in the blood and/or urine, either alone or in combination, may help diagnose or suggest a specific metabolic abnormality. These include serum levels of lactate, pyruvate, lactic acid dehydrogenase, uric acid, free and total carnitine, ketones, glucose, ammonia, myoglobin, liver transaminases, potassium, calcium, phosphate, creatinine, and acylcarnitine, and urinary levels of ketones, myoglobin, dicarboxylic acids, and acylglycines.

  • Urinary myoglobin excretion, which should be measured at rest and with exercise, can be induced by inborn errors of glycogen/glucose metabolism, fatty acid metabolism, and some mitochondrial DNA defects. The induction of myoglobinuria by pure exertion or by toxic factors, such as infection and fever, may suggest a particular disorder. As an example, a clinical presentation with features of a Reye-like syndrome or with myoglobinuria induced by toxic factors suggests a fatty acid oxidation defect [15].

    Patients with acute myoglobinuria may have concurrent elevations of serum creatinine, potassium, phosphate, uric acid, and even amino acids (particularly taurine). The serum calcium is usually low, but hypercalcemia may develop after recovery from renal failure.
  • The serum creatine kinase (CK) concentration should be tested at rest and during episodes of acute recurrent irreversible muscle dysfunction, with or without myoglobinuria. In patients with glycogen defects, the CK level may be elevated at rest, particularly in patients with static symptoms. By comparison, the CK level in patients with CPT II deficiency may be normal between acute episodes.
  • Dicarboxylic acids (DCAs) are detected in the urine of all patients with intramitochondrial beta-oxidation defects. This change is not seen with defects involving the transport of long-chain fatty acids into the mitochondria and also in carnitine uptake defects.
  • Serum levels of lactate and pyruvate may be elevated in patients with mitochondrial myopathies.
  • Significant elevation of CK levels with a normal LDH concentration raises the possibility of lactate dehydrogenase deficiency.
  • Modest hyperammonemia may be accompanied by elevated liver transaminases among patients with fatty acid oxidation defects who present with a Reye-like syndrome.

Lipid metabolism defects — In the patient with a suspected lipid metabolism defect, the determination of plasma total and free carnitine, serum acylcarnitines, urine acylglycines, and organic acids should preferably be performed during episodes of acute catabolic crises or periods of fasting. This is important because normal values may be observed when the patient is metabolically stable and not fasting. A fasting study is NOT recommended given the possibility of precipitating an acute catabolic crisis leading to death. (See "Causes of metabolic myopathies".)

The presence of a fatty acid metabolism disorder is supported by the following findings:

  • The combination of hypoketosis and hypoglycemia.
  • A serum free fatty acid to ketone ratio of more than 2:1 (normal ratio is 1:1) [1].
  • Specific abnormalities in serum carnitine concentrations. The value of carnitine determination in suspected fatty acid metabolism defects is illustrated in the Table (table 2). In carnitine uptake defects, the total serum carnitine is very low. In comparison, total serum carnitine concentrations are usually normal or low in fatty acid metabolism defects, except for CPT I deficiency, a disorder in which they may be normal or increased due to defective esterification of long-chain fatty acids to carnitine. In addition, the ratio of free carnitine to total carnitine is usually normal or low in most fatty acid metabolism defects, except for CPT I deficiency in which the ratio is high [25]. If serum acylcarnitines are elevated, the further separation and identification of the individual acylcarnitines could prove useful in the diagnosis of specific defects. (See "Causes of metabolic myopathies".)
  • An amount of DCAs which is equal to or higher than the amount of ketones (if the urine specimen was obtained after a period of fasting). However, the absence of DCAs in the urine does not rule out a fatty acid metabolism defect. The type of excreted DCAs may also help in the identification of the specific metabolic defect [26].
  • The finding of specific acylglycines in small quantities in the urine with some fatty acid metabolism defects. These include short-chain acyl-CoA dehydrogenase (SCAD), medium-chain acyl-CoA dehydrogenase (MCAD), electron transfer flavoprotein (ETF), and ETF-coenzyme Q oxidoreductase deficiencies [1].

Electromyography — In patients with fixed weakness, electromyography may be useful in excluding a neuropathic process and providing evidence for a myopathic condition. Myotonic discharges may be observed in patients with myophosphorylase, acid maltase, and debrancher enzyme deficiency. In patients with excessive fatiguability, repetitive nerve stimulation may be instrumental in excluding a defect in neuromuscular transmission [24]. (See "Overview of electromyography".)

Forearm exercise testing — Both anaerobic (ischemic) and aerobic forearm exercise testing may be helpful in evaluating patients suspected of having some type of metabolic myopathy.

Ischemic exercise — The forearm ischemic exercise test should be performed if the clinical evaluation and laboratory findings suggest an enzymatic defect in the nonlysosomal glycogenolytic pathway and in glycolysis. This test may be useful in assessing all patients with exercise intolerance [27]. However, children younger than five years of age may not be cooperative with the testing protocol.

The test begins with the placement and stabilization of a needle in a superficial antecubital vein of the arm to be exercised. Resting blood samples are obtained for serum lactate, pyruvate, CK, and ammonia. The blood pressure cuff is inflated to a pressure level above the diastolic pressure and the patient is asked to perform one per second hand grips with at least 75 percent of the maximum voluntary hand grip. The duration of the ischemic exercise test is one minute in the absence of cramping, but the cuff should be immediately deflated if an acute cramp develops.

Some recommend that the test be performed without the blood pressure cuff in place (ie, non-ischemic forearm exercise test) [28,29]; most inflate the cuff to a value intermediate between the systolic and diastolic blood pressures to permit systolic blood flow. In certain patients, inflation of the blood pressure cuff above the systolic pressure carries some risk of focal rhabdomyolysis, myoglobinuria, and acute compartment syndrome [30].

If the patient tolerates the test and exercises adequately, a single blood sample of CK and sequential samples of lactate, pyruvate, and ammonia are obtained at intervals of 1, 2, 3, 5, and 10 minutes after one minute of intermittent handgrip exercise. In normal individuals after a good effort, a three- to fivefold rise in lactate is noted within the first one to three minutes. The rise in serum ammonia is similar, but somewhat slower and more robust (5- to 10-fold over baseline); ammonia reaches a peak at three to four minutes.

Various abnormalities in the forearm ischemic exercise test may be observed with different metabolic disorders (table 4) [31]:

  • The rise in lactate is less than twofold among patients with inborn errors of glycolysis/glycogenolysis; however, the increase in ammonia is normal in patients who have made sufficient effort during the test.
  • Lactate production may be absent or diminished in phosphorylase, phosphofructokinase, debrancher, phosphoglycerate mutase, phosphoglycerate kinase, and LDH enzyme deficiencies. In the last condition, there is no rise in lactate levels, but pyruvate levels rise normally.
  • The lactate curve is normal in acid maltase and in most cases of phosphorylase b kinase deficiencies [1], probably related to differential activation mechanisms for muscle phosphorylase [32,33].
  • In patients with mitochondrial myopathies, there may be excessive production of lactate at submaximal levels of effort, but this is not a universal finding. With the non-ischemic forearm exercise test, the production of lactate is not sufficiently specific or sensitive for the diagnosis of mitochondrial disorders [34].
  • With myoadenylate deaminase deficiency, there is absence of ammonia production with normal responses of venous lactate and pyruvate.
  • The level of CK may rise in both glycogenolytic/glycolytic and fatty acid oxidation defects. The forearm ischemic exercise test is normal in defects of fatty acid metabolism as far as the lactate and ammonia curves are concerned.

Aerobic exercise — There is less experience with aerobic forearm exercise testing, but it may be a valuable method for differentiating mitochondrial myopathies from muscular dystrophy [35].

The aerobic forearm exercise test begins with a determination of a patient's maximal voluntary hand grip or maximal voluntary contraction (MVC), using a dynamometer or a rolled sphygmomanometer cuff. Once an estimate of the MVC is made, the patient is allowed to rest for 30 minutes, meanwhile, a venous cannula is placed in the antecubital vein, and a baseline sample of blood is obtained and refrigerated for later blood gas analysis. After the baseline sample has been obtained, exercise is begun (40 percent of MVC for one second alternating with one second of rest) and continued for three minutes. Additional blood samples are obtained during exercise at one minute intervals for three minutes. The venous blood samples are then analyzed for their oxygen saturation.

Using the technique described above, 12 patients with various forms of mitochondrial myopathy had a mean decrease of only seven percent (range +15 to -32 percent) while 12 healthy subjects and 10 patients with muscular dystrophy had mean decreases in antecubital vein oxygen saturation during exercise of 43 percent and 38 percent, respectively [35]. There was no overlap between the decrease in oxygen saturation of either healthy subjects (-34 to -54 percent) or muscular dystrophy (-33 to -54 percent) when compared to values obtained for those with mitochondrial myopathies. The need for blood gas analysis limits this test to sites with such equipment. Children may not be able to cooperate with the testing protocol.

Magnetic resonance spectroscopy — Nuclear magnetic resonance (NMR) spectroscopy is a noninvasive method for the study of muscle metabolism [36]. Its use is limited since it is unavailable in most institutions. If used, the absence of intracellular acidification during exercise suggests a glycolytic defect. In mitochondrial defects, the ratio of inorganic phosphate to phosphocreatine at rest is elevated, with delayed resynthesis of phosphocreatine after exercise [37,38].

Unlike NMR spectroscopy, proton magnetic resonance spectroscopy (MRS) can be performed with available clinical MR equipment. Limited data suggest that the technique may be useful in the diagnosis and in monitoring of therapy in carnitine palmitoyl transferase II deficiency [39].

Muscle biopsy — A muscle biopsy should be performed only after obtaining preliminary blood and urine tests, and, in some patients, electromyography and a forearm ischemic exercise test. Given the impracticality of testing muscle biopsy tissue for all known metabolic defects, the initial clinical and laboratory assessment helps target subsequent immunohistochemical and biochemical testing of muscle tissue.

Microscopic examination of the muscle sample should include electron microscopy, and immunohistochemical staining for phosphorylase, phosphofructokinase, and myoadenylate deaminase, if deficiencies in these enzymes are diagnostic possibilities. Microscopic examination will determine the presence or absence of glycogen or lipid storage, or the presence of ragged-red fibers in mitochondrial myopathies.

Since all of these evaluations will be normal in a number of metabolic defects, additional biochemical evaluation of muscle tissue should be pursued through commercial or research laboratories. In this setting, analysis will need to be focused upon specific possible biochemical defects, based upon the results of the preliminary noninvasive evaluation. In some instances, it may be possible to perform the direct enzymatic assay in cultured skin fibroblasts. This assay will be profitable diagnostically only if the enzymatic defect is expressed in this cell type.

Molecular techniques — Specific defects can be characterized at the molecular level either by Western blotting or by molecular analysis of specific mutations. Western blotting can be used to differentiate between a kinetic deficiency versus a defect in the production of the relevant enzyme. The identification of specific mutations can be used to precisely and rapidly detect specific defects and also to carry out presymptomatic, or prenatal diagnosis, and carrier detection.

Energy metabolism in muscle

Disclosures

Last literature review version 19.2: May 2011 | This topic last updated: July 24, 2009 (More)

INTRODUCTION — Patients with metabolic myopathies have underlying defects of energy production in muscle. Most affected patients have dynamic symptoms, such as exercise intolerance, muscle pain, and cramps upon exercise, rather than static symptoms, such as a fixed weakness of a specific muscle group.

To better understand these disorders, this topic review provides an overview of energy metabolism in muscle. The classification, diagnosis, and treatment of the metabolic myopathies are presented separately. (See "Approach to the metabolic myopathies" and "Causes of metabolic myopathies" and "Overview of disorders of glycogen metabolism" and "Mitochondrial myopathies: Clinical features and diagnosis".)

Prior to a review of the pathways of energy metabolism, it is helpful to first briefly review the sources of energy in muscle.

ENERGY SUBSTRATES IN EXERCISING MUSCLE — The main types of "fuel" used by muscle for energy metabolism are glycogen, glucose, and free fatty acids [1-3]. The particular energy sources used by working muscle for aerobic metabolism depend upon a number of factors including the intensity, type, and duration of exercise, physical conditioning, and diet [4,5]:

  • At rest, muscle predominantly uses fatty acids [1].
  • During high-intensity, isometric exercise, anaerobic glycolysis, and the creatine kinase reaction, in which phosphocreatine is converted to adenosine triphosphate (ATP), are the primary sources of energy [2].
  • With submaximal exercise, the type of substrate used by muscle is heavily dependent upon the relative intensity of exercise. During low-intensity submaximal exercise, the main sources of energy are blood glucose and free fatty acids. With high-intensity submaximal exercise, the proportion of energy derived from glycogen and glucose is increased, and glycogen becomes the main source. Fatigue is experienced when glucose and glycogen stores are depleted (as when a marathon runner hits the "wall").

Sources of muscle energy also vary with the duration of exercise. During the first hour of mild, low-intensity exercise (such as jogging), glucose, glucagon, and free fatty acids are the major sources of energy. The uptake of free fatty acids by muscle increases substantially during one to four hours of mild to moderate prolonged exercise; after four hours, lipid oxidation becomes the major source of energy (table 1) [6]. (See "Exercise physiology".)

ENERGY METABOLISM IN MUSCLE — Muscle contraction and relaxation depend primarily upon energy derived from hydrolysis of adenosine triphosphate (ATP). A number of biochemical processes in muscle fibers are responsible for maintaining a constant supply of ATP. These include:

  • Glycogen or glucose metabolism
  • Oxidative phosphorylation
  • Creatine kinase (CK) reaction by which phosphocreatine is converted to ATP
  • Purine nucleotide cycle
  • Lipid metabolism

Glycogen or glucose metabolism — Energy generation via the metabolism of glycogen or glucose in muscle occurs either anaerobically or aerobically.

Anaerobic glycolysis — Anaerobic glycolysis supplies energy in relatively rare circumstances. This pathway is primarily used during conditions of high-intensity, sustained, isometric muscular activity (eg, lifting heavy objects), particularly in the setting of limited blood flow and oxygen supply to exercising muscle fibers.

Phosphorylase, phosphorylase b kinase, and the debranching enzymes are responsible for the production of glucose-1-phosphate from glycogen (figure 1) [7]. The rate-limiting step in glycolysis, however, is the conversion of fructose-6-phosphate to fructose-1,6-diphosphate by the enzyme phosphofructokinase (PFK). The last step in glycolysis is the conversion of pyruvate to lactate by lactate dehydrogenase.

The development of fatigue is related to the increased concentration of lactate within muscle fibers, thereby resulting in acidification of the muscle cell. The accumulation of inorganic phosphate (Pi), adenosine diphosphate (ADP), and the monovalent form of organic phosphate are also important in fatigue generation [8,9]. As an example, maximal acute exercise to exhaustion is associated with a systemic pH as low as 6.80 and serum lactate concentrations as high as 20 to 25 meq/L [10].

Aerobic glycolysis — During dynamic forms of exercise (isotonic), such as walking or running, aerobic glycolysis appears to play an important role in energy production. With aerobic glycolysis, pyruvate is formed through the same steps described in anaerobic glycolysis, but oxidative decarboxylation of pyruvate takes place through the pyruvate dehydrogenase complex, generating acetyl coenzyme A (acetyl-CoA). The latter compound enters the tricarboxylic acid (TCA) cycle, also known as the citric acid cycle or Krebs cycle, where it is converted into carbon dioxide and water (figure 2) [11,12].

Oxidative phosphorylation — The oxidative phosphorylation system, localized in the inner mitochondrial membrane, is the main source of energy in muscle and other cells (figure 2). Compared to glycolysis, this system produces 17 to 18 times as much adenosine triphosphate (ATP) from the same amount of glucose.

The respiratory chain is composed of four multi-subunit complexes (I, II, III, and IV) linked by the mobile electron carriers coenzyme Q and cytochrome c. The reduced forms of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) are formed from the citric acid cycle and the beta-oxidation of fatty acids in the mitochondrial matrix. The respiratory chain transfers electrons from NADH (via complex I) and from reduced flavoproteins (via complex II and electron transfer flavoprotein-coenzyme Q oxidoreductase [ETF- Qo]) to coenzyme Q, then complex III, cytochrome c and finally complex IV, where they combine with molecular oxygen to form water. The flow of electrons releases energy that is used in the phosphorylation of ADP to ATP by complex V (ATP synthetase), which is also embedded in the inner mitochondrial membrane [13,14].

Phosphocreatine pathway — During very high intensity exercise, rapid formation of ATP can be accomplished through the reaction of phosphocreatine with ADP catalyzed by creatine kinase. Because the amount of phosphocreatine in muscle is small, the duration of this reaction is very brief. When oxygenation of muscle again becomes adequate, stores of phosphocreatine are replenished.

Purine nucleotide cycle — Intensely exercising muscle can generate ATP over a short period of time using the adenylate kinase reaction; this reaction catalyzes the conversion of two ADP molecules into one molecule of ATP and one molecule of adenosine monophosphate (AMP). The AMP may then be deaminated to inosine monophosphate (IMP) by myoadenylate deaminase, with concurrent production of ammonia (figure 3) [15]. Myoadenylate deaminase activity seems to be higher in type 2, fast muscle fibers.

Lipid metabolism — The metabolism of lipids in muscle occurs via beta- and omega-oxidation of fatty acids.

Beta-oxidation of fatty acids — At rest, fatty acids are the major energy substrate for muscle. Long-chain fatty acids constitute a major source of energy for prolonged, low-intensity exercise, lasting for more than 40 to 50 minutes [16]. Fatty acids are derived from circulating, very low-density lipoproteins in the bloodstream or from triglycerides stored in adipocytes.

Once in the cytoplasm, short- and medium-chain fatty acids of less than 10 carbon atoms can cross both the outer and inner mitochondrial membranes; these compounds subsequently enter the mitochondrial matrix where they undergo beta-oxidation after activation into their CoA esters (figure 4).

However, the mitochondrial membrane is not permeable to long-chain fatty acids; a multi-step process is therefore required for these compounds to be used by mitochondria. In the muscle cytoplasm, long-chain fatty acids are first activated by long-chain acyl-CoA synthetase to their CoA thioesters. The CoA thioesters are subsequently linked with carnitine by the enzyme carnitine palmitoyltransferase I (CPT I), which is located on the inner side of the outer mitochondrial membrane. The acylcarnitine form of the long-chain fatty acid, palmitoylcarnitine, is then transferred across the inner mitochondrial membrane by carnitine:acylcarnitine translocase [17]; once in the mitochondrial matrix, it is converted back to free acyl-CoA derivative and carnitine by CPT II, which is localized on the inner side of the inner mitochondrial membrane (figure 4).

Once carnitine is released, the long-chain acyl-CoA derivative enters the beta-oxidation pathway. With every complete cycle, a two-carbon fragment is cleaved and an acetyl-CoA molecule is released. The acetyl-CoA is then oxidized via the citric acid cycle for energy production in muscle, heart, and other tissues (figure 2) [8].

Ninety percent of the hepatic acetyl-CoA, however, is converted into ketones, which are an important source of energy for all tissues, particularly the brain. During prolonged fasting, ketones provide an important source of energy in brain tissue because the blood-brain barrier is impermeable to long-chain fatty acids [18]. The intramitochondrial beta-oxidation of fatty acids requires the existence of chain-length specific enzymes. The complete oxidation of fatty acids is mediated by at least 11 enzymes (table 1) [19,20].

Omega-oxidation of fatty acids — During prolonged fasting, as much as 20 percent of total cellular oxidation of fatty acids is accomplished in liver peroxisomes through omega-oxidation, thereby resulting in the formation of dicarboxylic acids (DCAs). DCAs are further metabolized through mitochondrial beta-oxidation.

The peroxisomal fatty acid oxidation enzymes are genetically distinct from the mitochondrial enzymes [16]. In mitochondria, the first step of beta-oxidation occurs via a flavin adenine dinucleotide (FAD)-containing enzyme coupled to oxidative phosphorylation that generates adenosine triphosphate (ATP). In peroxisomes, however, beta-oxidation occurs via a flavin-containing oxidase that generates H2O2 and then, through peroxisomal catalase, H2O and O2 [21]. Therefore, some energy is wasted. In mitochondria, the next steps in beta-oxidation are managed by two separate enzymes, while in peroxisomes they are managed by a single multifunctional enzyme protein.

It is believed that fatty acid oxidation in peroxisomes handles very-long-chain fatty acids (>C22), because these accumulate, particularly in neural tissues, in genetically linked peroxisomal disorders such as Zellweger syndrome and adrenoleukodystrophy. (See "Peroxisomal disorders".)

In metabolic defects of intramitochondrial fatty acid oxidation, mitochondrial beta-oxidation of DCAs is impaired at a time when the production of DCAs is increased due to the recruitment of peroxisomal omega-oxidation [22], hence the detection of DCAs in the urine. However, DCAs are also produced in other settings, including normal fasting, diabetic ketoacidosis, and diets containing medium-chain triglycerides. In addition, thioesterases catalyze the deacylation of coenzyme A and the conjugation of the acyl groups to glycine and to carnitine [23,24]. Thus, the detection of acylcarnitine derivatives in serum, and the detection of dicarboxylic acids and acylglycines in urine, has proven useful in the diagnosis of inborn errors of fatty acid oxidation [25,26].

Impairments at any of the important regulatory steps of lipid metabolism can lead to a myopathy and, in some cases, involvement of other organs. (See "Causes of metabolic myopathies".)





Интересный момент - дисфункция митохондрий может вызвать проблему выработки желудочной кислоты (очень энергозатратный процесс) И работу костного мозга и как следствие дифицит гемоглобина и от туда уже другие проблемы. Так же дисфункция митохондрий может вызывать проблемы с щитовидкой и регулированием сахара. Хотя говорят, что анемия и дефицит желаза маловероятны как причина сбоя в митохондриях, хоть железо и является необходимым элементов для ферментов в митохондрии. Про медь не понятно. Но куча других факторов может влиять на митохондрию. Всё закольцовано и работает как в одну сторону, так и в другую.
Page generated Jun. 9th, 2025 06:58 pm
Powered by Dreamwidth Studios